IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2.
The levels and activities of endogenous IL-6 in malignant pleural effusions due to lung cancer before and during daily intrapleural instillations of recombinant IL-2 were examined by enzyme immunoassay and bioassay using an IL-6-dependent murine hybridoma cell line MH60.BSF2. Before therapy, malignant pleural effusions contained various levels of IL-6. Daily intrapleural instillation of recombinant IL-2 for treatment of malignant pleurisy resulted in significant augmentation of the levels and activities of IL-6 in the pleural effusions. On fractionation of the pleural effusion by chromatography, one major peak of material with a mol. wt of 24 kD showed IL-6 activity. In contrast, no significant level of tumour necrosis factor-alpha or IL-1 beta was detectable in pleural effusions before or during local IL-2 therapy. These data suggest that IL-2 is an important regulatory factor of secondary IL-6 production.
Yanagawa
H
H
Third Department of Internal Medicine, School of Medicine, University of Tokushima, Japan.
Sone
S
S
Munekata
M
M
Atagi
S
S
Nii
A
A
Ogura
T
T
D000230:Adenocarcinoma / Q000276:immunology; D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology; D018288:Carcinoma, Small Cell / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000276:immunology; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000096:biosynthesis / Q000378:metabolism*; D008175:Lung Neoplasms / Q000276:immunology; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology
D007376:Interleukin-2; D015850:Interleukin-6